Provided by Tiger Trade Technology Pte. Ltd.

OCUMENSION-B

5.280
-0.060-1.12%
Volume:446.12K
Turnover:2.39M
Market Cap:4.30B
PE:-22.59
High:5.550
Open:5.190
Low:5.190
Close:5.340
52wk High:9.340
52wk Low:4.040
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:1.25
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.234
ROE:-3.45%
ROA:-1.93%
PB:1.02
PE(LYR):-22.59
PS:3.94

Loading ...

ByteDance Spin-Off Secures $290 Million in Inaugural Funding, Reaching $1.5 Billion Valuation in AI Drug Discovery

Deep News
·
Yesterday

Hong Kong Stock Movement | OCUMENSION-B (01477) Climbs Over 3% Following NDA Acceptance by Chinese Regulator

Stock News
·
Yesterday

Groundbreaking for Lingyu Pharma's Advanced Complex Injection Facility Aims to Elevate 'Made in China' to Global Standards

Deep News
·
Sep 15

AI Drug Discovery Firm Founded by Shanghai Jiao Tong University Professor Secures Series C1 Funding, a Global First

Deep News
·
Sep 15

MGI Tech Surges Over 8% in A-Share Trading as Virtual Cell Initiative Moves Toward Industrial Application With Baidu BioGene Partnership

Stock News
·
Sep 14

ST南新收到监管罚单 受损投资者维权路径探讨

Deep News
·
Sep 14

Cheaper US Drug Prices Could Push Costs Higher Globally, Study Finds

Stock News
·
Sep 14

Nicox Says China Regulator Accepts NCX 470 NDA for Review

Reuters
·
Sep 11

Ocumension's NDA For Ocular Treatment Approved in China

MT Newswires Live
·
Sep 11

Ocumension Therapeutics Says NMPA Accepts NDA for OT-301 (NCX 470, Bimatoprost Grenod)

Reuters
·
Sep 11

OCUMENSION-B (01477) NDA for OT-301 Accepted by Chinese Drug Regulator

Stock News
·
Sep 11

Ocumension Says China NMPA Accepts OT-301 Glaucoma Drug Application

Reuters
·
Sep 11

Ocumension Therapeutics - Nmpa Accepts Nda for Ot-301 (Ncx 470, Bimatoprost Grenod) in China

THOMSON REUTERS
·
Sep 11

Ascletis Pharma Surges on US Obesity Drug Trial Launch

Deep News
·
Sep 10

UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick

Stock News
·
Sep 09

HK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth

Stock News
·
Sep 09

The AI Drug Discovery Sector Enters Its Value-Realization Phase, Unlocking Fresh Growth Avenues for Innovative Medicines

Deep News
·
Sep 08

Ionis Pharmaceuticals Shares Slide 13.1% in Pre-Market Trading

Deep News
·
Sep 08

ASC36 Obesity Therapy Enters Phase I Trials in the US by Ascletis

Stock News
·
Sep 08

Nanxin Pharmaceutical Receives Penalty for Disclosure Violations, Affected Investors May Seek Compensation

Deep News
·
Sep 08